FIELD: chemistry.
SUBSTANCE: in claimed co-crystalline form molar ratio of 2-hydroxybenzamide and salicylic acid constitutes 1:1. Co-crystalline form is characterised by peaks at 2θ(°) 11.5, 14.8, 16.7, 18.8, 22.2, 23.5, 27.0 by the data of measurement of X-ray radiation diffraction on powder, and has endothermic peak from 116 to 124°C by the data of measurement by means of differential scanning calorimetry. Claimed co-crystalline form can be applied for manufacturing pharmaceuticals.
EFFECT: increased solubility of 2-hydroxybenzamide.
7 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
CO-CRYSTALLINE FORM OF ISONIAZID | 2016 |
|
RU2630957C1 |
HYDRATE OF CIPROFLOXACIN SALT WITH 4-AMINOBENZOIC ACID | 2019 |
|
RU2706351C1 |
CO-CRYSTALLINE FORMS OF THEOPHYLLINE | 2022 |
|
RU2805752C2 |
CO-CRYSTALLINE FORM OF 1-[(5-PARA-METHYL-META-CHLORO-PHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2019 |
|
RU2721335C1 |
Authors
Dates
2015-01-20—Published
2013-12-24—Filed